Stock comparison
Integra LifeSciences
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IART
Integra LifeSciences
Market cap
$1.17B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IART | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 26F | 75B | IDXX |
| Benjamin Graham | 40D | 80A | IDXX |
| Philip Fisher | 23F | 75B | IDXX |
| Peter Lynch | 21F | 71B | IDXX |
| Joel Greenblatt | 40D | 83C | IDXX |
| Charlie Munger | 22F | 87A | IDXX |
| Terry Smith | 15F | 84A | IDXX |
Side-by-side metrics
| Metric | IART | IDXX |
|---|---|---|
| Market cap | $1.17B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 42.6x | 31.6x |
| ROIC (TTM) | 3.49% | 40.66% |
| Gross margin | 53.21% | 62.05% |
| Net margin | -30.15% | 24.63% |
| Revenue CAGR 5y | 1.47% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 2.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IART leads on
- P/E (TTM)-vs 39.0x+106%
IDXX leads on
- Net margin24.63%vs -30.15%+182%
- Market cap$44.12Bvs $1.17B+97%
- ROIC (TTM)40.66%vs 3.49%+91%
- Revenue CAGR 5y7.56%vs 1.47%+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.